B&S S A : Investor presentation HY 2020

HY 2020 Investor Presentation | September 2020

HY 2020 Results

Performance highlights HY 2020

Covid-19 developments	Cost control measures		Solid financial position

▪ After a sales decline of 1.3% over Q1,	▪ Reducing opex, mainly comprising	▪ Decreased net debt position as a
the second quarter saw sales decline	staff costs, by bringing temporary	result of ongoing focus on working
by 12.1% (15.3% organically)	staff in line with sales volumes to	capital reduction
▪ Enhanced focus on online sales	the extent possible	▪ Cancellation of final dividend for
channels resulting in growth	▪ Utilising government support in the	2019
particularly in B2C	countries we are present	▪ Strong operating cash flow as a
▪ Swift recovery of value retail business	▪ All investment programs re-	result of matching purchase with
after the re-opening of shops starting	evaluated	sales levels and as such re-
in April		balancing inventory in line with
▪ Continuance of sales recovery in		market developments
Asian markets (albeit at low margins)
that started late Q1
▪ Standstill of cruise and travel retail
business

3

HY 2020 - Highlights

Turnover	▪ Overall: - 7.0% to € 835.8 M (- 7.9% on a constant currency basis)
▪	Organic: - 10.5% (- 11.5% on a constant currency basis)

Business segment

contribution

• HTG Liquors -9.1%
• HTG Health & Beauty -5.8%
• B&S +8.8%
• Retail -57.8%

EBITDA	▪ EBITDA of € 35.3 M (HY 2019: € 52.7 million)

M&A	▪ Lagaay Medical Group contributed to B&S segment

	▪ Net cash from operations of € 70.4 M (HY 2019: - € 0.4 M)
Financial position	▪	Inventory in days: 78 (HY 2019: 98)
	▪	Debtors in days: 35 (HY 2019: 38)

4